SCHEMBL3315112

SCHEMBL3315112

CCCN1CCC(Sc2cc3ccncc3cc2Cl)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.43
ROCK1 Q13464 1/20 0.43
DRD2 P14416 6/20 0.39
SLC6A4 P31645 2/20 0.38
HTR4 Q13639 2/20 0.37
NAMPT P43490 2/20 0.35
AKT1 P31749 1/20 0.35
IKBKB O14920 1/20 0.35
SIGMAR1 Q99720 1/20 0.34
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HTR7 P34969 1/20 0.34
HTR2B P41595 1/20 0.34
HTR3A P46098 1/20 0.34
HTR6 P50406 1/20 0.34
UBE2M P61081 1/20 0.34
DCUN1D1 Q96GG9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3316877 0.93 ROCK2 (0.38) ROCK2ROCK1DRD2AKT1IKBKB
SCHEMBL3309372 0.93 ROCK1 (0.40) ROCK2ROCK1DRD2SLC6A4HTR4
SCHEMBL3311776 0.91 AKT1 (0.36) ROCK2ROCK1NAMPTAKT1IKBKB
SCHEMBL3313689 0.88 ROCK2 (0.40) ROCK2ROCK1NAMPTAKT1SIGMAR1
SCHEMBL3315597 0.87 KDM2B (0.39) ROCK2ROCK1DRD2
SCHEMBL3315230 0.87 NR4A2 (0.36) ROCK2ROCK1DRD2AKT1IKBKB
SCHEMBL3315790 0.86 AKT1 (0.35) ROCK2ROCK1AKT1IKBKB
SCHEMBL3313662 0.86 IKBKB (0.43) ROCK2ROCK1DRD2SLC6A4HTR4
SCHEMBL3312561 0.86 ROCK2 (0.34) ROCK2ROCK1AKT1
SCHEMBL3311357 0.86 GSK3B (0.33) ROCK2ROCK1HTR4AKT1HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
EP-2114920-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES Sanofi-Aventis (FR) 2009-11-11 EP disclosed
WO-2008077552-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives MYLK2, MYLK, MYLK3 ROCK2 6/4885ROCK1 5/4885DRD2 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.